Skip to main content

Table 4 Stopping boundaries for early termination at interim analysis

From: Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

Analysis

Sample Size

Lower boundary

Upper boundary

1

30

5

11

2

36

6

13

3

42

7

14

4

48

15

16